Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
James N IngleNorth Central Cancer Treatment Group Trial N0032

Abstract

Fulvestrant is an antiestrogen that leads to estrogen receptor degradation and has demonstrated efficacy in breast cancer patients who have had disease recurrence or progression after tamoxifen. This study was designed to examine the efficacy and toxicity of fulvestrant in patients with disease progression on a third-generation aromatase inhibitor (AI). A one-stage phase II trial was conducted in postmenopausal women with measurable disease by Response Evaluation Criteria in Solid Tumors criteria who experienced disease progression after treatment with a third-generation AI and, at most, one additional hormonal agent. Tumors must have been estrogen receptor and/or progesterone receptor positive. The primary end point was objective response rate, and secondary end points were time to disease progression, survival, duration of response, and toxicity. Eighty patients were enrolled, and three were ineligible. Characteristics of the 77 eligible patients included median age of 68 years, performance score of 0 or 1 in 91% of patients, visceral dominant disease in 88% of patients, two prior hormonal treatments in 73% of patients, and prior chemotherapy for metastatic disease in 32% of patients. Eleven patients (14.3%) achieved a partia...Continue Reading

References

Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P E LønningG Massimini
Aug 25, 2001·Breast Cancer Research and Treatment·P E LønningA Howell
Aug 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HowellC Morris
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James N Ingle
Jun 2, 2004·Clinical Pharmacokinetics·John F R RobertsonDavid A Clarke
Nov 27, 2004·Breast Cancer Research and Treatment·Sandra FrancoCharles L Vogel
Jun 9, 2005·The Journal of Steroid Biochemistry and Molecular Biology·James N Ingle, Vera J Suman
Sep 21, 2006·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis

❮ Previous
Next ❯

Citations

Sep 12, 2008·Breast Cancer Research and Treatment·Paul E Goss
Jan 9, 2009·Breast Cancer Research and Treatment·Michael Patrick LuxN Harbeck
Mar 23, 2010·Medical Oncology·Celso A L MelloMarcello F Fanelli
Aug 1, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Laura Rodríguez LajusticiaSara López-Tarruella Cobo
Nov 5, 2013·Nature Genetics·Dan R RobinsonArul M Chinnaiyan
Oct 31, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J F R RobertsonL Petruzelka
Sep 22, 2006·Current Opinion in Oncology·Gianfilippo Bertelli, Robert Paridaens
Jan 16, 2007·Current Opinion in Obstetrics & Gynecology·Xiao-ping Gao, Fang Liu
Oct 3, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P NevenJ VAN Ginderachter
Jan 16, 2009·Breast Cancer Research : BCR·Stephen R D Johnston
Mar 21, 2012·Breast Cancer Research : BCR·Keerthi Gogineni, Angela DeMichele
Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BinesM E F Costa
Jun 27, 2007·Breast Cancer Research and Treatment·Patrick NevenIgnace Vergote
Nov 21, 2007·Expert Review of Anticancer Therapy·Monica Arnedos, Ian Smith
Nov 5, 2011·Expert Review of Anticancer Therapy·Jonathan KrellCarlo Palmieri
Jun 28, 2007·Expert Opinion on Investigational Drugs·Paolo CarliniGianluigi Ferretti
Feb 3, 2016·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Edith A Perez
Jul 7, 2011·Clinical Breast Cancer·Anthony Howell, Francisco Sapunar
Jun 30, 2009·Clinical Breast Cancer·Stephen R D Johnston
May 19, 2007·Clinical Breast Cancer·Elyse E LowerJames L Wade
Mar 21, 2008·The Breast : Official Journal of the European Society of Mastology·Stephen Chia, William Gradishar
Aug 28, 2007·The Breast : Official Journal of the European Society of Mastology·V Craig JordanRamona Swaby
May 22, 2007·Hematology/oncology Clinics of North America·Hope S Rugo
Aug 31, 2007·Journal of the American Geriatrics Society·Leona DowneyAlison Stopeck
Jul 18, 2015·Trends in Endocrinology and Metabolism : TEM·Christoforos Thomas, Jan-Åke Gustafsson
May 27, 2015·Nature Reviews. Clinical Oncology·Christopher D HartAngelo Di Leo
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Melinda Wu, Paul E Goss
Apr 22, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Khalil ZamanPatrick Neven
Mar 5, 2014·The Breast : Official Journal of the European Society of Mastology·Eva CiruelosHernán Cortes-Funes
Dec 3, 2014·Clinical Breast Cancer·John F R RobertsonJulia M W Gee
Mar 31, 2012·Clinical Journal of Oncology Nursing·Nancy Zeller Smith
Aug 23, 2016·Expert Review of Clinical Pharmacology·Francesca PoggioLucia Del Mastro
Oct 11, 2005·Trends in Endocrinology and Metabolism : TEM·Anthony Howell
Mar 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony M Brade, Ian F Tannock
Jan 28, 2018·Investigational New Drugs·Clinton YamBanu Arun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

© 2021 Meta ULC. All rights reserved